Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid
- PMID: 9400599
- DOI: 10.1006/viro.1997.8810
Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid
Abstract
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid (4-guanidino-Neu5Ac2en) specifically inhibits the influenza virus neuraminidase (NA) through interaction of the guanidino group with conserved Glu 119 and Glu 227 residues in the substrate binding pocket of the enzyme. To understand the mechanism by which influenza viruses become resistant to 4-guanidino-Neu5Ac2en, we investigated mutations at amino acid residues 119 and 227 in the influenza virus NA for their effects on this compound and on NA activity. The NA gene was cloned from the NWS-G70c virus, and mutations were introduced at the codon for amino acid residue 119 or 227. All of the 13 mutants containing a change at residue 119 were transported to the cell surface, although their expression levels ranged from 68.2 to 91.3% of wild type. Mutant NAs that retained at least 20% of the wild-type enzymatic activity were tested for their sensitivity to 4-guanidino-Neu5Ac2en and found to be sevenfold less sensitive to this compound than was the wild-type NA. By contrast, only 6 of 13 mutants defined by modifications at residue 227 were transported to the cell surface, and those NAs lacked substantial enzymatic activity (9% of wild type, at most). These results suggest that only a limited number of resistant viruses arise through mutations at Glu 119 and Glu 227 under selective pressure from 4-guanidino-Neu5Ac2en and that the development of compounds which interact with 227 Glu more strongly than does 4-guanidino-Neu5Ac2en may reduce the likelihood of drug-resistant viruses still further.
Similar articles
-
Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en.Virology. 1995 Dec 20;214(2):475-84. doi: 10.1006/viro.1995.0058. Virology. 1995. PMID: 8553549
-
Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en.Virology. 1995 Dec 20;214(2):642-6. doi: 10.1006/viro.1995.0078. Virology. 1995. PMID: 8553569
-
Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid.Virology. 1995 Oct 1;212(2):323-30. doi: 10.1006/viro.1995.1489. Virology. 1995. PMID: 7571401
-
Zanamivir. A potent and selective inhibitor of influenza A and B viruses.Clin Pharmacokinet. 1999;36 Suppl 1:v-ix. Clin Pharmacokinet. 1999. PMID: 10429834 Review. No abstract available.
-
Zanamivir: from drug design to the clinic.Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1885-93. doi: 10.1098/rstb.2001.1021. Philos Trans R Soc Lond B Biol Sci. 2001. PMID: 11779388 Free PMC article. Review.
Cited by
-
An adenovirus vector-mediated reverse genetics system for influenza A virus generation.J Virol. 2007 Sep;81(17):9556-9. doi: 10.1128/JVI.01042-07. Epub 2007 Jun 27. J Virol. 2007. PMID: 17596315 Free PMC article.
-
Zanamivir: a review of its use in influenza.Drugs. 1999 Oct;58(4):761-84. doi: 10.2165/00003495-199958040-00016. Drugs. 1999. PMID: 10551442 Review.
-
Generation of influenza A viruses entirely from cloned cDNAs.Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9345-50. doi: 10.1073/pnas.96.16.9345. Proc Natl Acad Sci U S A. 1999. PMID: 10430945 Free PMC article.
-
Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses.J Virol. 2006 Sep;80(17):8787-95. doi: 10.1128/JVI.00477-06. J Virol. 2006. PMID: 16912325 Free PMC article.
-
Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies.Antimicrob Agents Chemother. 2000 Jan;44(1):78-87. doi: 10.1128/AAC.44.1.78-87.2000. Antimicrob Agents Chemother. 2000. PMID: 10602727 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources